What exactly did Raymond James do on March 09, 2026?

Raymond James reiterated a **Strong Buy** for Kalaris on **March 09, 2026** at **10:57 AM**. The research note maintained the recommendation but did not include a new price target. The action is a maintenance of the prior bullish stance.

How should I interpret the KLRS analyst rating for trading decisions?

Use the KLRS analyst rating as one input. A maintained Strong Buy signals conviction but not guaranteed returns. Check cash runway, catalysts, and liquidity before trading. Consider position size relative to coverage risk and diversify accordingly.

Was a new KLRS price target issued with this note?

No. Raymond James did not disclose a new price target in the March 09, 2026 note. StreetInsider lists price at time as N/A, so the note is a reaffirmation without a fresh target.

How does the Meyka AI grade relate to the KLRS analyst rating?

Meyka AI rates KLRS with a grade of **B**, reflecting benchmark comparison, sector results, growth, key metrics, and analyst consensus. The grade complements the KLRS analyst rating but is not investment advice.

Analyst Ratings

Raymond James Maintains Strong Buy on KLRS Kalaris Therapeutics Inc Mar 2026

ByDanny Kontos March 10, 2026

Raymond James maintained a Strong Buy on Kalaris Therapeutics Inc (KLRS) on March 09, 2026. The note was issued at 10:57 AM and the firm reiterated conviction despite no new price target disclosed. This KLRS analyst rating update is a maintenance call, not a change, and it follows limited recent coverage. The StreetInsider summary shows a measured market response of 1.11% ($0.11) since the note. We examine what this KLRS analyst rating means for investors and how it ties to valuation and market reaction.